Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)

William J. Scott; Martin F. Hentemann; R. Bruce Rowley; Cathy O. Bull; Susan Jenkins; Ann M. Bullion; Jeffrey Johnson; Anikó Redman; Arthur H. Robbins; William Esler; R. Paul Fracasso; Timothy Garrison; Mark Hamilton; Martin Michels; Jill E. Wood; Dean P. Wilkie; Hong Xiao; Joan Levy; Enrico Stasik; Ningshu Liu; Martina Schaefer; Michael Brands; Julien Lefranc

doi:10.1002/cmdc.201600148

journal article Open Access Jun 16, 2016

Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)

William J. Scott Martin F. Hentemann R. Bruce Rowley Cathy O. Bull Susan Jenkins Ann M. Bullion Jeffrey Johnson Anikó Redman Arthur H. Robbins William Esler R. Paul Fracasso Timothy Garrison Mark Hamilton

Martin Michels Jill E. Wood Dean P. Wilkie Hong Xiao

Joan Levy Enrico Stasik Ningshu Liu Martina Schaefer Michael Brands Julien Lefranc

ChemMedChem Vol. 11 No. 14 pp. 1517-1530 · Wiley

View at Publisher Save 10.1002/cmdc.201600148

Abstract

AbstractThe phosphoinositide 3‐kinase (PI3K) pathway is aberrantly activated in many disease states, including tumor cells, either by growth factor receptor tyrosine kinases or by the genetic mutation and amplification of key pathway components. A variety of PI3K isoforms play differential roles in cancers. As such, the development of PI3K inhibitors from novel compound classes should lead to differential pharmacological and pharmacokinetic profiles and allow exploration in various indications, combinations, and dosing regimens. A screening effort aimed at the identification of PI3Kγ inhibitors for the treatment of inflammatory diseases led to the discovery of the novel 2,3‐dihydroimidazo[1,2‐c]quinazoline class of PI3K inhibitors. A subsequent lead optimization program targeting cancer therapy focused on inhibition of PI3Kα and PI3Kβ. Herein, initial structure–activity relationship findings for this class and the optimization that led to the identification of copanlisib (BAY 80‐6946) as a clinical candidate for the treatment of solid and hematological tumors are described.

Topics

No keywords indexed for this article. Browse by subject →

References

43

[1]

The Phosphoinositide 3-Kinase Pathway

Lewis C. Cantley

Science 10.1126/science.296.5573.1655

[2]

10.1007/s00109-015-1352-5

[3]

10.1016/j.pharmthera.2014.09.006

[4]

10.1006/excr.1999.4701

[5]

10.1038/nrc3860

[6]

Vogt P. K. Curr. Top. Microbiol. Immunol. (2010)

[7]

10.1126/science.1096502

[8]

10.4161/cc.8.9.8255

[9]

10.1016/j.gde.2009.11.002

[10]

PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control

M.-M. Georgescu

Genes & Cancer 10.1177/1947601911407325

[11]

10.1016/j.semcdb.2003.12.021

[12]

10.1038/nrm3330

[13]

10.1073/pnas.0802655105

[14]

10.1158/0008-5472.can-09-2525

[15]

10.18632/oncotarget.207

[16]

10.1158/1535-7163.mct-13-0518

[17]

10.1158/1078-0432.ccr-11-1446

[18]

10.1038/oncsis.2013.46

[19]

10.3892/or.2013.2520

[20]

10.1016/s0360-3016(03)00214-1

[21]

10.1158/0008-5472.can-09-0823

[22]

10.2174/1568009611313020007

[23]

10.1111/nyas.12060

[24]

10.1517/13543776.2013.779673

[25]

10.1016/j.coph.2015.05.016

[26]

10.1007/s40265-014-0285-6

[27]

10.1016/j.ccr.2010.10.031

[28]

10.1038/onc.2008.247

[29]

10.1158/0008-5472.can-10-0409

[30]

10.1038/46319

[31]

10.1016/s1097-2765(05)00089-4

[32]

10.1016/j.cell.2006.03.035

[33]

Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring

Martin Andrs, Jan Korabecny, Daniel Jun et al.

Journal of Medicinal Chemistry 10.1021/jm501026z

[34]

10.1038/nchembio.293

[35]

Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ

John R. Somoza, David Koditek, Armando G. Villaseñor et al.

Journal of Biological Chemistry 10.1074/jbc.m114.634683

[36]

10.1021/jm501624r

[37]

M.Shimada T.Murata K.Fuchikami H.Tsujishita N.Omori I.Kato M.Miura K.Urbahns F.Gantner K.Bacon(Bayer Pharmaceuticals Corp.) WO 2004029055 (20030918) 2004.

[38]

10.1039/jr9480000376

[39]

10.1002/prac.19341390703

[40]

10.1021/jo00338a003

[41]

10.1021/jo00427a028

[42]

M.Hentemann J.Wood W. J.Scott M.Michels A.-M.Campbell A.-M.Bullion R. B.Rowley A.Redman(Bayer Schering Pharma AG) WO 2008070150 (20071205) 2008.

[43]

10.1158/1535-7163.mct-12-0993-t

Cited By

112

Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models

Chiara Tarantelli, Martin Lange · 2020

Blood Advances

Metrics

112

Citations

43

References

Details

Published: Jun 16, 2016
Vol/Issue: 11(14)
Pages: 1517-1530
License: View

Authors

W

William J. Scott

Global Development Global Program Management Bayer HealthCare Pharmaceuticals Inc. Whippany NJ 07981 USA

M

Martin F. Hentemann